A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With

See also
Status	Clinical Trial	Phase
Completed	`NCT01427881` - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00006473` - Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT00003196` - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	N/A
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Terminated	`NCT01678443` - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Phase 1
Active, not recruiting	`NCT01815749` - Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	Phase 1
Completed	`NCT01588015` - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	Phase 1
Completed	`NCT02933320` - BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia	Phase 1/Phase 2
Withdrawn	`NCT02281279` - Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Terminated	`NCT01408043` - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	N/A
Terminated	`NCT00288067` - Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT00098891` - MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT00118170` - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Phase 1
Completed	`NCT03187262` - A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia	Phase 2
Completed	`NCT01748721` - MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Phase 1
Terminated	`NCT00096005` - Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Phase 1
Terminated	`NCT00101244` - SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00040846` - Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Phase 2
Completed	`NCT00005799` - Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	N/A

NCT number	NCT04052854
Study type	Expanded Access
Source	BeiGene
Contact
Status	No longer available
Phase

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms